Latrepirdine (Dimebon) is a pro-neurogenic, antihistaminic compound that has yielded mixed results in clinical trials of mild to moderate Alzheimer's disease, with a dramatically positive outcome in a Russian clinical trial that was unconfirmed in a replication trial in the United States. We sought to determine whether latrepirdine (LAT)-stimulated amyloid precursor protein (APP) catabolism is at least partially attributable to regulation of macroautophagy, a highly conserved protein catabolism pathway that is known to be impaired in brains of patients with Alzheimer's disease (AD). We utilized several mammalian cellular models to determine whether LAT regulates mammalian target of rapamycin (mTOR) and Atg5-dependent autophagy. Male TgCRND8 mice were chronically administered LAT prior to behavior analysis in the cued and contextual fear conditioning paradigm, as well as immunohistological and biochemical analysis of AD-related neuropathology. Treatment of cultured mammalian cells with LAT led to enhanced mTOR-and Atg5-dependent autophagy. Latrepirdine treatment of TgCRND8 transgenic mice was associated with improved learning behavior and with a reduction in accumulation of Ab42 and a-synuclein. We conclude that LAT possesses pro-autophagic properties in addition to the previously reported pro-neurogenic properties, both of which are potentially relevant to the treatment and/or prevention of neurodegenerative diseases. We suggest that elucidation of the molecular mechanism(s) underlying LAT effects on neurogenesis, autophagy and behavior might warranty the further study of LAT as a potentially viable lead compound that might yield more consistent clinical benefit following the optimization of its pro-neurogenic, pro-autophagic and/or pro-cognitive activities.
INTRODUCTION
Latrepirdine (Dimebon; dimebolin) is a neuroactive compound with antagonist activity at histaminergic, a-adrenergic and serotonergic receptors. 1 Based on its effects on cognition in rodents, 2--6 taken in conjunction with its highly favorable safety profile, the compound has formed the basis for clinical trials for both Alzheimer's disease (AD) 7 and Huntington's disease (HD), 8 despite a poor understanding of the molecular mechanisms underlying its putative mnemoactive properties. Latrepirdine has been reported to possess several properties that are potentially relevant to the treatment of neurodegenerative diseases: (1) protection of cultured cells from the cytotoxicity of amyloid-b (Ab) peptide; 9 (2) stabilization of mitochondrial function and calcium homeostasis; 1 (3) modulation of Ab release from cultured cells, isolated intact nerve terminals, and from hippocampal neurons in living mouse brain; 10 and (4) promotion of neurogenesis in the murine hippocampus. 11 We reported that latrepirdine (LAT) stimulates APP catabolism and Ab secretion, 10 an unexpected result for a drug that was claimed to benefit AD. In pursuit of a parsimonious subcellular mechanism underlying this unexpected result, we considered the possibility that LAT-stimulated Ab release might occur via an unconventional secretory pathway associated with induction of macroautophagy (autophagy), 12 a highly regulated process that can be activated in response to various stressful conditions. 13 Several laboratories have demonstrated that autophagy has a neuroprotective role in cell and animal models of neurodegene-rative diseases, including AD, HD 14 and Parkinson's disease. 15 Converging data indicate that therapeutic manipulation of autophagy with rapamycin can improve behavioral function and arrest neuropathology in at least two mouse models of AD. 16--18 To this end, small molecule enhancers of rapamycin (SMERs; most notably SMER-28) induced autophagy, improved cell viability and promoted clearance of neurodegenerative diseaserelated proteins including APP metabolites (among them Ab, 19 huntingtin 20 and a-synuclein 20 ) in cellular models. Herein, we report the following: (1) LAT modulates Atg5-dependent autophagic activity in a dose-dependent manner and via the mTOR-signaling pathway; (2) LAT potentiates the degradation of APP metabolites in cell culture and in mouse brain; and (3) LAT improves the memory behavior of TgCRND8 mice while reducing the accumulation of insoluble Ab42. Given the pressing need for effective disease-modifying treatment for symptomatic AD and the current evidence that Ab-lowering agents might only be effective for prophylaxis, 21 we argue that identification of the molecular basis of the pro-cognitive and antineurodegeneration actions of LAT remains highly valuable.
MATERIALS AND METHODS

Preparation and handling of latrepirdine
The synthesis and characterization of LAT was described previously. 10 Briefly, latrepirdine was purchased from SinoChemexper (Shanghai, China) and purity of the compound was determined to be 499%, or provided directly by Medivation (San Francisco, CA, USA). For use in vitro, latrepirdine was dissolved directly into culture media to the desired concentration, as described in Steele et al. 10 For administration in vivo, latrepirdine was dissolved in 0.9% saline (vehicle) at a final concentration of 3.5 mg ml À1 (made fresh every 2 days).
Cell culture experiments 
Behavioral testing
Mice were trained and tested in operant chambers on three consecutive days in the cued and contextual fear conditioning paradigm, similar to that described in Jacobsen et al. 22 See Supplementary Methods for detailed protocol. Freezing behavior was recorded remotely and analyzed using Stoelting ANY-MAZE Fear Conditioning Software (Stoelting, Wood Dale, IL, USA).
Statistical analysis
Integrated density of immunoreactive western blot bands or spots was measured using MultiGauge Software and normalized to % control (vehicle or non-transgenic littermates (nTg), where indicated). Absolute concentrations of monomeric Ab40 and Ab42 or oAb were normalized to initial tissue weight. In all instances, Shapiro-Wilk test of normality and Levene's test for homogeneity of variance were utilized for inclusion in parametric tests (P40.05 for Shapiro-Wilk and Levene's tests). Independent samples t-tests (parametric design) or Mann--Whitney U tests (nonparametric design) were utilized to determine significant mean differences between two groups. One-way analysis of variance (parametric analysis) or Kruskal--Wallis test (nonparametric analysis) were used to compare three or more groups, depending on whether the data fit the assumptions of parametric analysis (see above). Two-way analyses of variance were used to analyze CHX time-course experiments with regard to effects of time and treatment, and interactions. Bonferroni's or Dunn's correction for multiple comparisons were utilized depending on whether data fit the assumptions of parametric or nonparametric design, respectively. Significance for t-tests and analyses of variances are reported with a Pp0.05 using two-tailed tests with an a-level of 0.05. All statistical analyses were performed using SPSS v18.0 and/or GraphPad Prism 5 (La Jolla, CA, USA).
RESULTS
Acute latrepirdine treatment induced autophagy via the mTORpathway in cultured cells We sought to determine whether LAT might regulate autophagy as one mechanism of its reported anti-neurodegeration activity. We treated HeLa cells stably expressing LC3 fused with EGFP (eGFP-LC3) 23 for 3 or 6 h in the absence or presence of 50 mM latrepirdine. Treatment with latrepirdine for 3 (data not shown) or 6 h ( Figure 1a ) markedly enhanced the number of eGFP-LC3 punctae, indicating that LAT induced the formation of autophagosomes.
Next, mouse N2a neuroblastoma cells were treated in the absence (vehicle) or presence of 5, 500 or 50 mM LAT for 3 or 6 h in order to determine the effects of acute drug treatment on the regulation of autophagy. We observed a significant and dosedependent increase in LC3-II levels in N2a cells following 3 or 6 h treatment with either 5, 500 nM or 50 mM LAT (Figure 1 ). Because the inhibition of autophagic clearance also results in accumulation of LC3-II, we chose to assay the levels of p62, which is readily degraded by autophagy, and which accumulates when autophagic clearance is inhibited (see Supplementary Figure 1 ). The p62 levels did not increase in the presence of 500 nM or 50 mM LAT; instead, 50 mM LAT caused a trend toward reduction of p62 levels at both 3 and 6 h treatment (Figures 1a and c) , suggesting that LC3-II accumulation was associated with increased autophagosome formation and activity.
We next examined the mTOR signaling pathway, which is a key regulator of autophagic activity. 24 mTOR kinase activity can be monitored by the levels of phosphorylated-mTOR (p-mTOR; serine 2448) and the levels of the phosphorylated form of its substrate, ribosomal S6 protein kinase (p70S6K; p-S6K). 25 We observed a significant decrease of p-mTOR and p-S6K from N2a cells treated with 50 mM LAT for 3 h, whereas the total mTOR and p70S6K levels remained relatively constant ( Figure 2 ). Based on this result, we conclude that LAT likely induced autophagy via inhibition of the mTOR signaling pathway. The specific molecular target of latrepiridine within this pathway remains unknown.
Latrepirdine-induced degradation of p62 and APP metabolites was Atg5-dependent We treated ATG5 þ / þ wild type (WT) or ATG5À/À MEFs for 3 h in the absence or presence of 50 mM LAT ( Table 1 ). In contrast, incubation of WT MEFs with 50 mM LAT for 3 h resulted in a trend toward decreased APP-CTFs, suggesting that the accumulation of APP-CTFs and a resultant pool of Ab may be a result of autophagic activity that is partially relieved following addition of LAT. In ATG5À/À MEFs, incubation with 50-mM LAT for 3 h did not result in any change in APP-CTF or p62 accumulation, confirming that the LAT-related stimulation of clearance of APP metabolites and p62 was Atg5-dependent. We tested whether LAT altered the accumulation of intracellular APP metabolites using stable SweAPP (APP K670N,M671L )-overexpressing N2a cells (the generous gift of Dr Gopal Thinakaran). N2a SweAPP cells were treated for 3 h in the absence or presence of 50-mM LAT. Cell lysates and conditioned media were separately analyzed for APP metabolites by western blot. We observed a significant accumulation of LC3-II and without the accumulation of p62, indicating enhanced autophagy. Moreover, we noted parallel changes in levels of both intra-and extracellular APP metabolites (Figures 2f--l) , in which the induction of autophagy was associated with decreased intracellular Ab accumulation and a trend toward increased secreted Ab. These changes are consistent with our previous report that LAT stimulates the secretion of APP metabolites, 10 suggesting that LAT may reduce intracellular APP/ Ab accumulation by stimulating both secretion of APP metabolites and intracellular catabolism of APP/Ab via autophagy.
Twenty-four-hour LAT treatment arrested lysosomal degradation of APP metabolites and p62 in cultured cells containing a defective autophagy pathway Unexpectedly, following a 24 h treatment of MEFs or N2a SweAPP cells with 50 mM LAT, we observed significant hyperaccumulation of LC3-II, p62 and APP metabolites, a profile consistent with an inhibition of autophagy, potentially via inhibition of end-stage lysosomal protease activity. This effect was observed in both the presence (N2a SweAPP cells or WT MEFs) or absence (ATG5À/À MEFs) of an intact autophagic pathway and was therefore Atg5-independent. Although LAT inhibited mTOR signaling following brief drug treatments, no regulation of the mTOR pathway could be detected following 24 h exposure of cells to the drug (Figures 3a and e) . This effect appeared to be distinct from the regulation of autophagic activity observed with short-term exposure to latepirdine. (a--e) Mouse embryonic fibroblasts (MEFs) derived from wild-type or ATG5À/À mice were treated for 3 h in the absence (VEH; Ctrl) or presence of 50-mM latrepirdine (LAT). Lysates were analyzed by western blot for levels of p-S6K, total S6K, p62 and LC3 and a/b-CTFs (using the panspecies pAb 369). (f--l) N2a cells stably overexpressing Swedish APP were treated for 3 h in the absence (VEH; Ctrl) or presence of 50-mM latrepirdine (LAT). Lysates were analyzed by western blot for levels of p-S6K, total S6K, p62 and LC3. Lysates and conditioned medium were also analyzed by western blot for levels of intracellular (IC Ab, holoAPP, C99-CTF) or secreted (sAPPa and sAb) APP metabolites, respectively, with the human APP-specific mAb 6E10. All figures are representative of three or more independent experiments, performed in duplicate or triplicate. Graphs are mean ± s.e.m.; A related report demonstrated that some histamine-related compounds were associated with an off-target and receptorindependent vacuolar-ATPase-dependent inhibition of lysosomal protonation when used at high concentrations and with long incubation times (similar to the conditions used here). 26 We propose that this effect may underlie our observation that 24 h incubation with 50-mM LAT potentiates the accumulation of typical p62 and APP-CTFs, even in the absence of an intact autophagic pathway (Figures 3e--k) .
Impaired autophagic clearance of a-synuclein and LC3 occurred as a delayed pathology following accumulation of insoluble Ab42 and p62 in the brains of TgCRND8 mice An aging-dependent decrease in basal neuronal turnover of brain autophagic substrates has been identified as a feature of the molecular neuropathology associated with the progression of AD. Here, we hypothesized that autophagic/lysosomal failure leads to the hyperaccumulation of typical autophagic substrates, including APP metabolites, a-syn, LC3 and p62. Along this line, it is relevant that cortical accumulation of a-syn, a known autophagic substrate, is observed in 30--50% of AD patients. 27 Here, we utilized the TgCRND8 (APP K670N/M671L/V717F ) mouse model of Alzheimer's cerebral amyloidosis. 28 Male TgCRND8 mice or their nTg were killed at 3 or 4 months of age, and cerebral cortices were dissected for analysis of levels of the APP metabolites, a-syn, p62 and LC3 in both soluble and insoluble fractions (for schematic, see Supplementary Figure 2 ). By 3 months of age, TgCRND8 mice were impaired in acquisition and learning reversal in the reference memory version of the Morris water maze task. 28 At 3 months of age, TgCRND8 mice exhibited deposition of Ab42-immunoreacive cortical and hippocampal plaques and accumulation of insoluble p62, which was recovered along with Ab42 in the 70% formic acid fraction of extracts of TgCRND8 brain; however, neither LC3 nor a-syn were ever detectable in the formic acid fractions. When 3-month-old mice were studied, no significant difference was observed between genotypes in the levels of soluble a-syn, LC3-I, LC3-II or p62 (Figure 4c ), suggesting Figure 3 . 24 h incubation with 50-mM latrepirdine potentiates Atg5-independent accumulation of APP metabolites and p62. (a--d) Mouse embryonic fibroblasts (MEFs) derived from either wild-type or ATG5À/À mice were incubated for 24 h in the absence or presence of 50-mM latrepirdine. Cell lysates were analyzed for levels of APP metabolites, as well as markers of autophagy including LC3, P62, S6K and pS6K by western blot. (e--k) N2a cells stably overexpressing Swedish APP (N2a SweAPP) were incubated for 24 h in the absence or presence of 50-mM latrepirdine. Cell lysates and conditioned media were analyzed for levels of APP metabolites, as well as markers of autophagy including LC3, P62, S6K and pS6K by Western blot. All figures are representative of three or more independent experiments, performed in duplicate or triplicate. Graphs are mean±s.e.m.; *Pp0.05; **Pp0.01; ***Pp0.001.
that autophagic clearance of these substrates is functionally intact at that age in TgCRND8 mice. However, by 4 months of age, we observed a significant increase in accumulation of soluble a-syn, total LC3 (LC3-I and LC3-II), and p62 and as insoluble p62 (Figure 4c ), suggesting the development of an aging-dependent impairment of autophagic clearance among TgCRND8 mice. Taken together, these results indicate that accumulation of insoluble Ab42 and p62 temporally precedes the impairment of autophagic clearance, and may lead to autophagic/lysosomal failure. In future studies, we plan to investigate the temporal relationship between insoluble Ab42 and p62 accumulation and alterations in autophagic/lysosomal stasis. Regardless of the cause and effect, these data indicate that autophagic/lysosomal failure may lead to the hyperaccumulation of autophagic substrates, accelerating disease progression.
Chronic LAT therapy was associated with improved cognition and reduced neuropathology in TgCRND8 mice Based on the total daily intake of latrpeirdine described by Doody et al., 7 an equivalent single intraperitoneal (i.p.) bolus in an adult mouse was determined to be 3.5 mg kg À1 per day, and we previously reported that acute administration of this dose increased the secretion of Ab40 into the interstitial fluid of the hippocampus of living Tg2576 mice. 10 The dosing regimen for the current study was chosen based on two primary considerations: (1) in vitro studies (herein), indicating that sustained high levels of LAT may inhibit autophagic clearance and (2) the observation that 21 consecutive (once daily) injections of 3.5 mg kg À1 LAT were sufficient to enhance (not inhibit) autophagy in young TgCRND8 mice (Supplementary Figures 3 and 4) . In related studies in Saccharomyces cerevisiae, we observed that LAT enhanced autophagy and promoted the clearance of Ab42 29 or a-syn.
30
Chronic LAT administration also promoted autophagy and the degradation of a-syn in the brains of wild-type mice. 30 On the basis of these results, we postulated that a once-daily i.p. bolus of 3.5 mg kg À1 LAT for 31 days might enhance autophagy and stimulate the clearance of autophagic substrates while avoiding the potential confounding of prolonged exposure to high concentrations of LAT (Figure 3) .
Male, 90-day-old TgCRND8 mice or their wild-type littermates (nTg) received 31 consecutive once-daily i.p. injections of either 3.5 mg kg À1 LAT or 0.9% saline (vehicle). At the culmination of treatment, mice were tested for cued and contextual fear conditioning using a paradigm that has been widely accepted for evaluating learning and memory deficits in APP transgenic mice. 31 No difference was noted for cued or contextual memory between vehicle-or LAT-treated nTg mice. We observed a significant increase in cued memory only among LAT-versus vehicle-treated TgCRND8 mice (P ¼ 0.01; Figure 5 ). A weak, nonsignificant trend toward an improvement in contextual memory among LAT-versus vehicle-treated mice (P ¼ 0.099) was also observed. Neither performance in the cued nor contextual memory tasks by LAT-treated TgCRND8 mice were sufficient to correct the animals to the level of performance observed for their nTg littermates. However, because TgCRND8 mice are known to be impaired in related tasks at 3 months of age, 28 we suggest that the effect of improved cued memory may be related to arrest of disease progression, rather than improved cognition per se.
Brain extracts were analyzed for soluble and insoluble APP metabolites, LC3, p62 and a-syn by western blot. No differences were observed between treatment groups for levels of soluble APP metabolites (including Ab, Figure 5 ). We further assayed the brain extracts for concentrations of soluble oligomeric oAb (oAb) subtypes that were dimeric or larger in structure. We observed a trend toward decreased mean soluble oAb levels among LAT-(1225 pg g À1 ) versus vehicle-treated (1318 pg g À1 ) TgCRND8 mice that did not reach statistical significance (P ¼ 0.0851). We also noted a significant decrease in soluble a-syn monomer (P ¼ 0.0042) in the brains of TgCRND8 mice, which was associated with significantly elevated LC3-II accumulation (P ¼ 0.0095) and without accumulation of soluble p62 ( Figure 5 ), confirming our results from pre-depositing 3-month-old TgCRND8 mice ( Supplementary Figures 3 and 4) .
Formic acid fractions (Triton X-100-'insoluble' material) were analyzed by Ab40-or Ab42-specific sandwich ELISA, and a significant decrease in the levels of insoluble Ab42 were observed when LAT-treated mice were compared with vehicle-treated mice (P ¼ 0.046; Figure 5 ). Western blot analysis of insoluble p62 levels revealed a modest, but statistically significant, decrease among LAT-versus vehicle-treated mice (P ¼ 0.0334). These results suggest that the cognitive benefits of LAT were associated with decreases in insoluble Ab42 and p62, and may be due to increased autophagic substrate clearance.
DISCUSSION
Protein aggregates are resistant to degradation and thus inherently long-lived; 32 therefore, maintenance of efficient intracellular and extracellular proteolysis is required in order to prevent accumulation of toxic aggregates. Following logically, from this consideration, is the notion that maintenance or restoration of optimal levels of autophagic flux may be of therapeutic benefit to several neurodegenerative diseases. 33 Indeed, recent reports indicate that activation of autophagy reduces intracellular accumulation of protein aggregates and improves cognition in three different mouse models of AD. 16--18,34,35 At the cellular level, the work presented here, and through collaborative works, 29, 30 indicates that activation of mTOR-dependent autophagy by rapamycin neutralizes the proteotoxicity induced in S. cerevisiae by a-syn 30 or Ab42. 29 When taken together with a wealth of published evidence, the principle emerges that pharmacological regulation of proteostasis in general, and of autophagy in particular, represents attractive potential interventions for treatment of some neurodegenerative diseases. Given the evidence that LAT has biological activity in TgCRND8 mice that includes activation of autophagy (reported herein), and that mTOR modulation of autophagy is much more effective as prophylaxis than as therapy for established AD in mouse models, 17 then (as appears to be the case with other therapies directed at Ab 21 ) LAT might be most useful in presymptomatic AD or in cases of mild cognitive impairment. However, if the current data are relevant to the clinical benefit observed in the Russian trial of LAT in mild-to-moderate AD, this would imply that symptomatic AD subjects might improve or have their disease progression arrested.
It is worth noting that we have not investigated the recently reported pro-neurogenic actions of LAT, 11 so we cannot comment on whether the autophagy modulation that we have observed has a role in the drug's reported pro-neurogenesis properties, although examination of this possible connection would be worth undertaking. However, as we are contemplating the treatment of neurodegenerative disorders, the putative proneurogenic action only makes the drug a more intriguing target for further investigation, as does its clean safety profile and blood-brain-barrier penetrability. The evidence reported herein suggest that, despite mixed results in clinical trials, LAT possesses potentially relevant biological activities and, as such, the drug may yet be useful as a lead scaffold for developing clinically safe, blood-brain-barrier-penetrating, pro-autophagic, pro-neurogenic drugs for treatment and/or prevention of cerebral proteinopathies, including a-synucleinopathies and Alzheimer's cerebral amyloidosis.
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